---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-006457"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2023-03-07T23:59:59+00:00"
generated_at: "2026-06-18T09:48:05.003560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Treace Medical Q4 rev $49.8M (+49% YoY); FY rev $141.8M (+50%); FY23 guide $187-193M

## Summary
- Q4 revenue $49.8M (+49% YoY); FY2022 revenue $141.8M (+50% YoY).
- Q4 net loss ($4.4M) or ($0.08)/share; Adjusted EBITDA positive $0.3M (vs loss $4.0M in Q4 2021).
- FY2022 net loss ($42.8M) or ($0.77)/share; Adjusted EBITDA loss ($23.7M).
- Completed follow-on offering raising net proceeds $107.5M; cash & securities $81.3M at year-end.
- FY2023 revenue guidance $187-193M (32-36% growth).

## SEC filing metadata
- accession: 0000950170-23-006457
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2023-03-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/0000950170-23-006457-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/tmci-20230307.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-006457
- JSON: https://secwatch.observer/filing/0000950170-23-006457.json
- Plain text: https://secwatch.observer/filing/0000950170-23-006457.txt

## Key facts
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported the fourth quarter ended December 31, 2022 results: revenue $49.8 million, net income ($4.4) million, or ($0.08) per share, EPS ($0.08) per share.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $49.8 million
  - Net income: ($4.4) million, or ($0.08) per share
  - EPS: ($0.08) per share
  - Result: reported results
  source text: of hallux valgus (commonly known as bunions), today reported financial results for the fourth quarter and full year ended December 31, 2022. Recent Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. •
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/0000950170-23-006457-index.htm
- Earnings Releases
  TREACE MEDICAL CONCEPTS, INC. reported the year ended December 31, 2022 results: revenue $141.8 million, net income ($42.8) million, or ($0.77) per share, EPS ($0.77) per share.
  - Period: the year ended December 31, 2022
  - Revenue: $141.8 million
  - Net income: ($42.8) million, or ($0.77) per share
  - EPS: ($0.77) per share
  - Result: reported results
  source text: Highlights: • Revenue of $49.8 million in the fourth quarter of 2022, a 49% increase over the same period last year and a 51% increase sequentially. Full year 2022 revenue of $141.8 million increased 50% over 2021. • Blended average revenue per Lapiplasty® procedure kit sold was $5,907, a 10% increase over the same period last year and a 2% increase sequentially.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1630627/000095017023006457/0000950170-23-006457-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.